盐酸缬更昔洛韦片治什么病？

It is an oral anti-cytomegalovirus infection drug developed by the Swiss company Roche. Its main ingredient is valganciclovir hydrochloride. What diseases does Valganciclovir Hydrochloride Tablets treat?

Roche announced on August 31, 2009 that the U.S. Food and Drug Administration (FDA) has approved Valcyte (trade name: Valcyte; generic name: valganciclovir hydrochloride) for the prevention of cytomegalovirus (CMV) infection in pediatric kidney and heart transplant patients aged 4 months to 16 years. Such children are considered to be a high-risk group for CMV infection.

In addition, the U.S. FDA also approved a new oral solution formulation of Vancevi to make it easier for children to take it.

Roche noted that approximately 80% of Americans have CMV infection. The virus is usually dormant but can become active when the immune system is compromised. In organ transplant patients, CMV infection usually occurs in the first few months after transplantation and can lead to pulmonary, renal, hepatic, gastrointestinal, and neurological complications. Research shows that CMV infection is associated with an increased risk of death in transplant patients. The safety and effectiveness of Vancevi in ​​preventing CMV infection in children younger than 4 months old after solid organ transplantation has not been proven.

In addition, the U.S. FDA has not approved this drug for the treatment of congenital cytomegalovirus infection. The metabolite of Vancevir is ganciclovir, and its clinical toxicity includes neutropenia, anemia and thrombocytopenia. In animal experiments, ganciclovir is carcinogenic, teratogenic, and causes azoospermia.

Valganciclovir hydrochloride tablets have previously been approved for the treatment of cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome. The drug is also used to prevent CMV infection in high-risk patients after kidney, heart, kidney, and pancreas transplants.

For the prevention of CMV infection in adult patients after organ transplantation, the recommended dose for kidney transplant patients is 900 mg (two 450 mg tablets) once daily, starting within 10 days after transplantation and continuing until 200 days after transplantation. For patients who have received a solid organ transplant other than a kidney, the recommended dose is 900 mg (two 450 mg tablets) once daily, starting within 10 days after transplantation and continuing until 100 days after transplantation.